Future studies should consider personalisation based on baseline haptoglobin concentrations in patients with T2DM rather than just Hp2-2 genotype to evaluate impact on the detailed lipid pathways, cardiac and renal physiology. The gene discussed is HP; the disease is type 2 diabetes mellitus.